AJP - Endo Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 293: E1078-E1084, 2007. First published August 14, 2007; doi:10.1152/ajpendo.00337.2007
0193-1849/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/4/E1078    most recent
00337.2007v2
00337.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weickert, M. O.
Right arrow Articles by Möhlig, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weickert, M. O.
Right arrow Articles by Möhlig, M.

A Thr94Ala mutation in human liver fatty acid-binding protein contributes to reduced hepatic glycogenolysis and blunted elevation of plasma glucose levels in lipid-exposed subjects

Martin O. Weickert,1,2 Christian v. Loeffelholz,1,2 Michael Roden,3 Visvanathan Chandramouli,4 Attila Brehm,3 Peter Nowotny,5 Martin A. Osterhoff,1,2 Frank Isken,1,2 Jochen Spranger,1,2 Bernard R. Landau,4 Andreas F. H. Pfeiffer,1,2 and Matthias Möhlig1,2

1Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal; 2Department of Endocrinology, Diabetes, and Nutrition, Charité-University-Medicine, Campus Benjamin Franklin, Berlin, Germany; 3First Medical Department, Hanusch Hospital, Karl-Landsteiner Institute for Endocrinology and Metabolism, Vienna, Austria; 4Department of Medicine, Case Western Reserve University, Cleveland, Ohio; and 5Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Submitted 29 May 2007 ; accepted in final form 1 August 2007


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 CONCLUSIONS
 GRANTS
 REFERENCES
 
Liver fatty acid-binding protein (L-FABP) is a highly conserved key factor in lipid metabolism. Amino acid replacements in L-FABP might alter its function and thereby affect glucose metabolism in lipid-exposed subjects, as indicated by studies in L-FABP knockout mice. Amino acid replacements in L-FABP were investigated in a cohort of 1,453 Caucasian subjects. Endogenous glucose production (EGP), gluconeogenesis, and glycogenolysis were measured in healthy carriers of the only common Thr94-to-Ala amino acid replacement (Ala/Ala94) vs. age-, sex-, and BMI-matched wild-type (Thr/Thr94) controls at baseline and after 320-min lipid/heparin-somatostatin-insulin-glucagon clamps (n = 18). Whole body glucose disposal was further investigated (subset; n = 13) using euglycemic-hyperinsulinemic clamps without and with lipid/heparin infusion. In the entire cohort, the only common Ala/Ala94 mutation was significantly associated with reduced body weight, which is in agreement with a previous report. In lipid-exposed, individually matched subjects there was a genotype vs. lipid-treatment interaction for EGP (P = 0.009) driven mainly by reduced glycogenolysis in Ala/Ala94 carriers (0.46 ± 0.05 vs. 0.59 ± 0.05 mg·kg–1·min–1, P = 0.013). The lipid-induced elevation of plasma glucose levels was smaller in Ala/Ala94 carriers compared with wild types (P < 0.0001). Whole body glucose disposal was not different between lipid-exposed L-FABP genotypes. In summary, the Ala/Ala94-mutation contributed significantly to reduced glycogenolysis and less severe hyperglycemia in lipid-exposed humans and was further associated with reduced body weight in a large cohort. Data clearly show that investigation of L-FABP phenotypes in the basal overnight-fasted state yielded incomplete information, and a challenge test was essential to detect phenotypical differences in glucose metabolism between L-FABP genotypes.

endogenous glucose production; gluconeogenesis; insulin resistance; free fatty acids; nutrigenomics; randomized controlled study

LIPID ACCUMULATION AND COMPARTMENTALIZATION in the liver are strongly associated with insulin resistance and are subject to nutritional influences (8, 31). High circulating concentrations of free fatty acids (FFA) induce both hepatic and peripheral insulin resistance (16). The transport and metabolism of FFA are mediated by fatty acid-binding proteins (FABPs), which are highly conserved and abundantly expressed in various tissues, including the liver. It has been suggested that FABPs are important factors for the fine-tuning of metabolic responses but are likely to influence metabolic homeostasis negatively under conditions of excessive caloric and fat intake (20). Supporting this concept, FABP knockout mice show no obvious phenotype under chow-fed conditions but are remarkably protected from fatty liver, insulin resistance, atherosclerosis, type 2 diabetes, and obesity when exposed to a high flux of fatty acids (20, 22) despite circulating concentrations of FFA not being reduced in these animals.

Liver-type FABP (L-FABP) accounts for up to 5% of the cytoplasmatic protein in hepatocytes (3) and is a key regulator of hepatic lipid metabolism by influencing the uptake, transport, mitochondrial oxidation, and esterification of fatty acids (1). L-FABP knockout mice that are exposed to high FFA concentrations by prolonged 48-h fasting show about 10-fold reduced liver fat (21), which might affect hepatic insulin sensitivity (31). Lower insulin concentrations in fed animals have been further reported (21), indicating improved glucose metabolism. Obviously, in humans, knockout models are not available. However, amino acid variations in L-FABP could be functionally relevant and thus exert a phenotype, particularly in lipid-exposed subjects. This is supported by observational studies showing associations of the common threonine (Thr)94-to-alanine (Ala) amino acid replacement in L-FABP with reduced body weight (7) and protection against high apolipoprotein B levels in Ala/Ala94 carriers that consume a high-fat, Western diet (24).

To date, potential contributions of amino acid variants in L-FABP to hepatic and peripheral glucose metabolism have not been reported. Thus, we first investigated all known polymorphisms leading to amino acid replacements in L-FABP. Only one of these coding polymorphisms was found in the subjects investigated, resulting in a Thr94-to-Ala amino acid replacement with a minor allele frequency of 36%. We then performed a randomized, single-blind, controlled intervention with nine healthy subjects carrying the Ala/Ala94 mutation vs. nine sex-, age-, and body mass index (BMI)-matched wild-type (Thr/Thr94) controls to assess endogenous glucose production (EGP), gluconeogenesis, and glycogenolysis at baseline and during 320-min lipid/heparin-insulin-glucagon-somatostatin clamps. Potential differences in lipid-induced peripheral insulin resistance between L-FABP genotypes were investigated in a substudy.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 CONCLUSIONS
 GRANTS
 REFERENCES
 
The Clinicaltrials.gov Identifier number for this study is NCT00277342 [ClinicalTrials.gov] .

Investigation of polymorphisms in L-FABP. All known polymorphisms leading to an amino acid replacement in L-FABP (Thr94Ala, Thr54Ala, and Leu42Ala) were first genotyped in 93 subjects. In these subjects, only the Thr94Ala variant was present and subsequently investigated in 1,453 participants of our cohort of metabolically characterized volunteers.

DNA of all participants was extracted from whole blood using Magnasep magnetic beads (Agowa, Berlin, Germany). The region around the polymorphisms was amplified by PCR (Thr94Ala: upper primer 5'-ACACGCTCAGAGCACCACCA, lower primer 5'-GACAGTGGTT-CAGTTGGAAG; Thr54Ala and Leu42Val: upper primer 5'-GTCTGCCGGAAGAGC-TCATC, lower primer 5'-CTGTCATTGTCTCCAGCTCA). Amplificates were controlled by restriction enzyme digestion. The single nucleotide polymorphism (SNP) diagnostic was performed by primer elongation using SnuPE (Thr94Ala: 5'-GGTGACAATAAACTGGTGACA; Thr54Ala: 5'-CTTCAAGTTCA-CCATCACC; Leu42Val: 5'-TCAAGGGGGTGTCGGAAATC; Amersham, Piscataway, NJ). Detection was performed on a MegaBACE 1000 (Molecular Dynamics, Sunnyvale, CA) using SNP profiler 1.0 software.

Participants of the intervention trial. The experimental protocol was approved by the local ethics committee, and all subjects gave written, informed consent. Healthy carriers of the homozygous Ala/Ala94 mutation with normal fasting glucose and normal glucose tolerance were recruited from 1,453 characterized volunteers. Exclusion criteria were impaired glucose metabolism as indicated by an oral glucose tolerance test, menstrual irregularities, a history of smoking, or a medication with cortisone. For nine of the subjects willing to participate, age-, sex-, and BMI-matched wild-type (Thr/Thr94) controls were selected (Table 1). Subjects were invited in random order according to their availability for participation in the study. The participants of the study and the researchers that performed the laboratory analyses were not aware of the L-FABP genotype. Fertile female subjects were studied in the early follicular phase of the menstrual cycle. Subjects were instructed to maintain normal physical activity for 3 days before all study days.


View this table:
[in this window]
[in a new window]

  		Table 1. Description of the age-, sex-, and BMI-matched participants enrolled in the intervention study

 
Experimental design. The design of the intervention studies is shown in Fig. 1, A and B. Subjects arrived at the metabolic unit in the morning after 10-h overnight fasts. To reduce variance, all subjects consumed standardized liquid meals at 10 PM on the evening before all study days (2 portions, Biosorp; Pfrimmer Nutricia, Erlangen, Germany). No other meals and only tap water were allowed in the 12 h before the studies. After arrival, two intravenous catheters were inserted into contralateral forearm veins. The arm at which blood samples were drawn was placed into a heating box (65°C) throughout the studies.


Figure 1
View larger version (15K):
[in this window]
[in a new window]

  		Fig. 1. Flow sheet of the experimental procedures. A: pancreatic clamp study (lipid/heparin-insulin-glucagon-somatostatin clamps; n = 18). Deuterium oxide (2H2O) for the assessment of gluconeogenesis was given in 4 equal doses. Thereafter, subjects had free access to water containing 0.5% 2H2O to maintain isotopic equilibrium. Twenty percent glucose (2% enriched with D-[6,6-2H2] glucose) was administered only when blood glucose was <4.4 mmol/l and immediately stopped when it was ≥4.4 mmol/l. {downarrow}Time points for taking baseline values (–150 min) and determination of endogenous glucose production (EGP) and gluconeogenesis (–30, –20, –10, +300, +310, and +320 min). {uparrow}Bolus: priming dose, adjusted to fasting glucose concentrations. B: euglycemic-hyperinsulinemic clamps without and with lipid infusion (substudy; n = 13). Euglycemic-hyperinsulinemic clamps were started at 0 min after administration of an insulin bolus at –10 min, adjusted for the body weight of the participants, and were performed for ≥2 h. In the steady-state condition of the clamp, arterialized plasma glucose was adjusted at 4.4 ± 0.4 mmol/l for ≥30 min. Thereafter (from 150 ± 7 min), a constant lipid/heparin infusion was administered for an additional 320 min. Arterialized plasma glucose was adjusted at 4.4 ± 0.4 mmol/l throughout the lipid/heparin infusion period. GIR, glucose infusion rate.

 
From –10 min, somatostatin (3 mg; Somatostatin Deltaselect, Dreieich, Germany) was infused to inhibit endogenous hormone secretion (Fig. 1A), followed by the replacement of insulin (Insuman Rapid; Aventis, Bad Soden, Germany) and glucagon (GlucaGen; Novo Nordisk, Mainz, Germany) within the low fasting range (Fig. 2, C and D). Plasma glucose concentrations are known to decrease during the first 2–3 h of somatostatin clamps (2, 19, 26). Therefore, to avoid hypoglycemic symptoms, a 2% enriched (99% [6,6-2H2]glucose; Euriso-Top, Saarbrücken, Germany), 20% glucose infusion (Glucose-20-pfrimmer; Baxter, Unterschleissheim, Germany) was administered when blood glucose was <4.4 mmol/l and immediately reduced/stopped when it was ≥4.4 mmol/l. Plasma FFA concentrations were raised from 0 min to +320 min by a constant lipid infusion (20% Deltalipid LCT; Deltaselect, Pfullingen, Germany) combined with heparin (Heparin-Natrium-25000-ratiopharm; Merckle, Blaubeuren, Germany) (Fig. 1A). Plasma glucose concentrations were allowed to rise freely after the start of the lipid/heparin infusion.


Figure 2
View larger version (27K):
[in this window]
[in a new window]

  		Fig. 2. Pancreatic clamp study. A, B, C, D, and E: peripheral concentrations of plasma free fatty acids (FFA; A), serum C-peptide (B), serum insulin (C), plasma glucagon (D), and serum growth hormone at baseline (–150 to –10 min) and during lipid challenge under somatostatin-insulin-glucagon clamp conditions (0 to +320 min) (E). Values are means ± SE for 9 age-, sex-, and body mass index (BMI)-matched alanine (Ala)/Ala94 carriers (bullet) and wild-type subjects ({circ}) in each group. F: lipid-induced changes in rates of EGP, gluconeogenesis (open bars), and glycogenolysis (gray bars). Data are expressed as fold difference in lipid-exposed subjects relative to the overnight-fasted state. After 320-min lipid/heparin infusion in the somatostatin-insulin-glucagon clamps there was a significant reduction in EGP (P = 0.007) and glycogenolysis (P = 0.015) in Ala/Ala94 carriers vs. wild-type subjects. Gluconeogenesis increased with no difference between genotypes (P = 0.65). Values are means ± SE for 9 age-, sex-, and BMI-matched subjects in each group. *P < 0.05; **P < 0.01. G: associated changes in plasma glucose concentrations at baseline (–150 to –10 min) and during lipid/heparin infusion under somatostatin-insulin-glucagon clamp conditions (0 to +320 min). P for genotype vs. lipid-treatment interaction <0.0001. Values are means ± SE for 9 age-, sex-, and BMI-matched Ala/Ala94 carriers (bullet) and wild-type subjects ({circ}) in each group. ***P < 0.0001.

 
A subset of the same subjects (7 wild types, 6 Ala/Ala carriers) was willing to participate again and was investigated on separate days for the assessment of whole body glucose disposal upon lipid exposure (Fig. 1B). Two-stepped euglycemic-hyperinsulinemic clamps were performed (euglycemic-hyperinsulinemic clamps from baseline until steady state, followed by an additional lipid/heparin infusion for an additional 320 min), with 40 mU·m–2·min–1 human insulin (Actrapid; Novo Nordisk, Bagsvaard, Denmark), a variable infusion of 20% glucose (Serag Wiessner, Naila, Germany), and a constant infusion of a lipid solution (20% Deltalipid LCT, 1.25 ml/min; Deltaselect, Pfullingen, Germany) and heparin (Heparin-Natrium-25000-ratiopharm, 0.4 IU·kg–1·min–1; Merckle). In the steady-state condition of the clamp (lasting ≥30 min) and throughout the lipid infusion period, arterialized plasma glucose was adjusted at 4.4 mmol/l.

Assays. Blood samples were drawn at timed intervals from –150 min to +320 min and immediately chilled and centrifuged, and the supernatants were stored at –80°C until analysis. Arterialized plasma glucose concentrations were measured immediately, using the glucose oxidase method on a Dr. Müller Super-GL glucose analyzer (Freital, Germany). Results for plasma glucose concentrations were confirmed after the experiments, using reagents from ABX Diagnostics (Montpellier, France) on a Pentra 400 (Horiba ABX Diagnostics). Measurements of C-peptide and insulin in serum and FFA, cholesterol, and triacylglycerols in plasma were performed as previously described (30). Plasma apolipoprotein B was measured on a Cobas-Mira (Roche, Lörrach, Germany), using reagents from ABX Diagnostics [intra-assay coefficient of variation (CV) 1.9%]. Plasma glucagon was measured by RIA (intra-assay CV 4.4%; DPC Biermann, Bad Nauheim, Germany). Serum growth hormone concentrations were measured using a two-phase chemoluminescence immunometric assay [Immulite 2000 growth hormone (human growth hormone), intra-assay CV 3.7%; DPC, Los Angeles, CA].

Assessment of EGP. For calculation of EGP (in mg·kg–1·min–1), a primed [0.06 (mg) x body wt (kg) x fasting plasma glucose (mg/dl), from –120 to –115 min], continuous [0.27 (mg) x body wt (kg), from –115 to +320 min] infusion of [6,6-2H2]glucose 99% (Euriso-Top, Saarbrücken, Germany) was administered. A basal period of 100 min was allowed for tracer equilibration. The priming dose was adjusted to fasting glucose concentrations to avoid overestimation of glucose production rates (17).

Assessment of the contribution of gluconeogenesis and glycogenolysis to EGP. At –150 min, subjects started to drink a total of 5 g 2H2O (99.9%; Euriso-Top) per kilogram body water, divided into four equal doses spaced at intervals of 45 min (17), for the assessment of gluconeogenesis. This was followed by free access to 0.5% 2H2O in tap water throughout the study to maintain isotopic steady state (Fig. 1A) (18). Body water was assumed to be 50% of body weight in women and 60% in men (18). Enrichments of 2H in the hydrogens bound to carbon 2 (C2) and carbon 5 (C5) of blood glucose were measured as previously detailed (9, 18, 27). 2H enrichment in plasma water was measured by an exchange with acetone as described by Yang et al. (33).

Calculations. Rates of EGP were determined from the tracer infusion rate of D-[6,6-2H2]glucose and its enrichment to the hydrogens bound to carbon 6 divided by the mean percent enrichment of plasma D-[6,6-2H2]glucose. Because tracer-to-tracee ratios were constant after 300 min, steady-state equations were appropriate for calculation of EGP. The percent contribution of gluconeogenesis to EGP was set to the ratio of 2H enrichment at C5 to that at C2. The percent contribution of glycogenolysis was calculated as [1 – (C5/C2)] x 100, and absolute contributions of gluconeogenesis and glycogenolysis were calculated by multiplying their percent contributions by the rate of EGP (29). Metabolic clearance rate of glucose (expressed in ml·kg–1·min–1) was calculated from the rate of disappearance of glucose divided by the mean glucose concentration over the respective time period (23). Whole body glucose disposal (M value) in the substudy was calculated from the glucose infusion rate (14). Homeostasis model assessment for insulin resistance (HOMA-IR) was calculated as [fasting insulin (mU/l) x fasting glucose (mmol/l)/22.5].

Statistical analyses. Results are presented as means ± SE. The genotypes of the entire cohort were compared by Kruskal-Wallis test (when comparing 3 categories) or Mann-Whitney test (when comparing two categories). The age-adjusted comparison was performed using analysis of covariances. For this purpose, BMI was 1/square root transformed to achieve normal distribution regarding the Kolmogoroff-Smirnoff test.

The age-, sex-, and BMI-matched subjects (Ala/Ala94 carriers vs. wild types) were compared using two-tailed Student's t-test for paired analysis or two-way-ANOVA with the Huynh-Feldt epsilon procedure as correction factor. Results from the substudy were compared using two-tailed Student's t-test for unpaired samples. Total area under the curve (AUC) was calculated using the trapezoid method. Statistical significance was defined as P < 0.05. Calculations were performed using SPSS version 12.0 (SPSS, Chicago, IL).


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
CONCLUSIONS
 GRANTS
 REFERENCES
 
Characteristics of the L-FABP genotype in the entire cohort. Only the A277-to-G polymorphism substituting Thr94 by Ala was detected in 93 subjects and subsequently investigated in the entire cohort (n = 1,453). Its minor allele frequency was 36% [41% wild-type Thr/Thr94 carriers, 46% heterozygous subjects (Thr/Ala94), and 13% homozygous Ala/Ala94 carriers (Ala/Ala94)]. The genotype distribution was not significantly different from the Hardy-Weinberg equilibrium. In the overnight-fasted state there were no significant differences in plasma cholesterol (P = 0.08), plasma triacylglycerols (P = 0.78), Hb A1c (P = 0.31), and HOMA-IR (P = 0.58) with respect to the genotypes.

There was, however, a significant difference in BMI (Thr/Thr wild types 29.5 ± 0.3, Thr/Ala 28.6 ± 0.2, Ala/Ala94 carriers 28.4 ± 0.4 kg/m2, P for comparing 3 categories = 0.04). This was explained by the difference in BMI between wild types (Thr/Thr) and Ala carriers (Thr/Ala or Ala/Ala). BMI of Ala carriers (28.6 ± 0.2 kg/m2) was significantly lower than the BMI of wild types (P = 0.012). Because of the significant difference in age (51.5 ± 0.6, 52.3 ± 0.5, 54.9 ± 1.0 yr, P for comparing 3 categories = 0.01), we additionally performed an age-adjusted comparison of BMI (P for comparing the 3 genotypes = 0.01, P for comparing wild types vs. Ala carriers = 0.003), which confirmed the lower BMI in Ala carriers compared with the wild types.

Characteristics of the subjects enrolled into the intervention studies. The matched subjects of the intervention trial (n = 18) did not differ in baseline parameters (Table 1).

EGP, gluconeogenesis, and glycogenolysis without lipid challenge (baseline study). Before the pancreatic clamp was started in 10-h overnight-fasted subjects (Fig. 1A), there were no significant differences in rates of EGP (wild types 1.92 ± 0.08 vs. Ala/Ala94 carriers 1.99 ± 0.12 mg·kg–1·min–1, P = 0.62), gluconeogenesis (0.96 ± 0.04 vs. 0.98 ± 0.04 mg·kg–1·min–1, P = 0.69), and glycogenolysis (0.96 ± 0.09 vs. 1.00 ± 0.10 mg·kg–1·min–1, P = 0.75) between L-FABP genotypes.

Pancreatic clamp study: peripheral concentrations (somatostatin-insulin-glucagon clamp). After start of the lipid/heparin infusions, FFA increased from +30 min (P < 0.001) and rose further within the range seen in uncontrolled diabetes from 240 min (>1.5 mmol/l), with no difference between groups (P = 0.86; Fig. 2A). After the start of somatostatin infusion, C-peptide concentrations decreased, indicating inhibition of insulin secretion with no difference between L-FABP genotypes (P = 0.64; Fig. 2B). Insulin and glucagon were replaced within the low fasting range, with no difference between groups (molar insulin/glucagon ratio between L-FABP genotypes, P = 0.42; Fig. 2, C and D). In the overnight-fasted state, growth hormone levels tended to be higher in Ala/Ala94 carriers but were not significantly different between L-FABP genotypes (P = 0.185; Fig. 2E), with high variance very likely to be explained by the known pulsatile secretion pattern of this hormone. Upon somatostatin infusion, growth hormone levels were completely suppressed in all subjects. There was no difference in growth hormone concentrations between L-FABP genotypes (P = 0.187, –150 to +320 min; Fig. 2E). Upon lipid challenge, plasma glucose levels were increased significantly less in Ala/Ala94 carriers compared with the wild types (P < 0.0001; Fig. 2G). Glucose concentrations expressed as AUC470min were reduced in Ala/Ala94 carriers vs. wild types (AUC470min 2,305 ± 72 vs. 2,503 ± 92 mmol·l–1·min–1, P = 0.002). Differences in plasma glucose concentrations between L-FABP genotypes were statistically significant from 180 min of lipid/heparin infusion.

Tracer-to-tracee ratios determined at 310 vs. 300 min and at 320 vs. 300 min were constant both in wild types (2.00 ± 0.12 vs. 2.01 ± 0.11, P = 0.54, and 1.99 ± 0.11 vs. 2.01 ± 0.11, P = 0.41) and in Ala/Ala94 carriers (2.21 ± 0.16 vs. 2.22 ± 0.16, P = 0.52, and 2.21 ± 0.16 vs. 2.22 ± 0.16, P = 0.45).

EGP, gluconeogenesis, and glycogenolysis in lipid-exposed subjects (somatostatin-insulin-glucagon clamp). When genotype (Ala/Ala94 carriers vs. wild types) and treatment (basal state vs. lipid infusion) were included in one model, two-way ANOVA showed a significant effect of the lipid treatment (P = 0.005) and a genotype-vs.-treatment interaction (P = 0.009) but no effect of the genotype per se (P = 0.78), indicating that lipid exposure was necessary to detect differences in EGP between L-FABP genotypes. During lipid infusion, EGP significantly decreased in Ala/Ala94 carriers (from 1.99 ± 0.12 to 1.69 ± 0.14 mg·kg–1·min–1, P = 0.002), and this decrease was attenuated and not statistically significant in wild types (from 1.92 ± 0.08 to 1.82 ± 0.09 mg·kg–1·min–1, P = 0.087). Relative to baseline, changes in EGP after 320-min lipid/heparin infusion were significantly different between genotypes (P = 0.007; Fig. 2F). Glucose infusion rates required to prevent a somatostatin-induced decrease of plasma glucose during the first hours of the somatostatin clamps (maximal rates 1.38 ± 0.24 vs. 1.01 ± 0.19 mg·kg–1·min–1 over 5 min, P = 0.18; time of maximal rates 80 ± 32 vs. 75 ± 2 min, P = 0.64) and metabolic clearance rates of glucose (1.54 ± 0.20 vs. 1.40 ± 0.21 ml·kg–1·min–1, P = 0.59) were not significantly different between Ala/Ala94 carriers and wild types.

Both glycogenolysis and gluconeogenesis contribute to EGP. The contribution of glycogenolysis to EGP after 320-min lipid/heparin infusion was significantly lower in Ala/Ala94 carriers vs. wild types (0.46 ± 0.05 vs. 0.59 ± 0.05 mg·kg–1·min–1, P = 0.013). Compared with the baseline, glycogenolysis was reduced by 54% in Ala/Ala94 carriers (P < 0.001) and by 38% in wild types (P < 0.001), and these reductions were significantly different between genotypes (P = 0.015) (Fig. 2F).

For the contribution of gluconeogenesis to EGP, there was an effect of lipid treatment (P = 0.003) but neither an effect of genotype per se (P = 0.83) nor a genotype-vs.-treatment interaction (P = 0.78). Gluconeogenesis increased by 29% in wild types (P = 0.003) and by 25% in Ala/Ala94 carriers (P = 0.015) during lipid treatment, with no difference between the genotypes (absolute rates P = 0.97, baseline changes P = 0.65; Fig. 2F). These results indicate that lipid/heparin infusions affected EGP and contribution of glycogenolysis dependent on the L-FABP genotype, whereas gluconeogenesis increased independently of the genotype.

Whole body glucose disposal in overnight-fasted and lipid-exposed subjects (substudy). Steady-state conditions were reached after 150 ± 7 min. Thereafter, lipid/heparin infusions were added for an additional 320 min (Fig. 1B). M values decreased in lipid-exposed subjects (6.93 ± 0.59 vs. 5.67 ± 0.75 mg·kg–1·min–1, P = 0.020; n = 13), reflecting lipid-induced peripheral insulin resistance. When comparing age-, sex-, and BMI-matched L-FABP genotypes (4 of the matched pairs from the main study), M values were not significantly different between L-FABP genotypes in the overnight-fasted state and even tended to be higher in wild types (7.04 ± 0.65 vs. 4.98 ± 0.64 mg·kg–1·min–1, P = 0.19), which was also in agreement with the estimated insulin resistance in nine matched pairs, as calculated with HOMA-IR (Table 1). After lipid exposure, there was not any difference in M values between L-FABP wild types and Ala/Ala94 carriers (3.89 ± 1.14 vs. 4.74 ± 0.62 mg·kg–1·min–1, P = 0.85). There was no difference in apolipoprotein B concentrations between lipid-exposed L-FABP genotypes (0.76 ± 0.07 vs. 0.75 ± 0.09 g/l, P = 0.92).


   CONCLUSIONS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 CONCLUSIONS
GRANTS
 REFERENCES
 
Markers of glucose metabolism are improved in fed L-FABP knockout mice, and these animals are resistant to high-fat-, Western diet-induced obesity and fatty liver (21). In contrast, absence of L-FABP exerts no obvious phenotype in mice in the overnight-fasted state (22). In humans, the in vivo significance of L-FABP is largely unknown. The present study shows that the common Thr94-to-Ala amino acid replacement in L-FABP contributed significantly to reduced hepatic glycogenolysis and less severe hyperglycemia in lipid-exposed humans and was further associated with reduced body weight in a large cohort. The observed phenotype shows obvious conformity with the phenotype observed in L-FABP knockout mice, indicating that the Ala94 replacement in L-FABP is likely to be physiologically relevant.

In the non-lipid-exposed, overnight-fasted state, commonly used markers of glucose metabolism such as fasting glucose, fasting insulin, or HOMA-IR were not different between L-FABP genotypes. In contrast, plasma glucose concentrations markedly increased in wild types vs. Ala/Ala94 carriers when FFA concentrations were raised about threefold above fasting levels, which is within the range seen in obese subjects postprandially after a high-fat meal (13). This was explained mainly by higher rates of glycogenolysis in wild types, whereas lipid-induced increases in gluconeogenesis were comparable between L-FABP genotypes. Although more pronounced hyperglycemia per se should be expected to inhibit hepatic glucose production (11), lipid challenge appeared to interfere with this inhibitory effect, suggesting more severe FFA-induced impairment of hepatic autoregulation in L-FABP wild types.

It has recently been reported that plasma glucose can rise in lipid-exposed subjects, despite unaltered or even decreased rates of EGP (26, 29), due to lipid-induced reduction of whole body glucose disposal (16, 25). Because L-FABP is expressed mainly in hepatocytes and enterocytes (3), differences in whole body glucose disposal between matched L-FABP genotypes after intravenous administration of lipids were unlikely. However, to exclude this possibility, a substudy was performed with the same participants on separate study days, which showed lipid-induced reduction of whole body glucose disposal in all subjects, as expected (16), but no differences between L-FABP genotypes. This is again in agreement with the phenotype described in lipid-exposed L-FABP knockout mice (22).

We can further confirm the previously reported association of the Ala94 allele with reduced body weight (7) in a larger cohort. Because lipid-induced increases in plasma glucose under nonclamp conditions are accompanied by increased insulin secretion, and hyperglycemic-hyperinsulinemic conditions have been shown to inhibit fatty acid oxidation (28), this could be a contributing factor to the observed differences in body weight between L-FABP genotypes.

The rationale for choosing the specific experimental setup in the present study needs to be discussed. In vitro, FFA increase gluconeogenesis through the activation of key gluconeogenic factors (32). However, in vivo, lipid-induced changes in gluconeogenesis were not generally associated with changes in EGP (5, 26, 29), which can be partly explained by hepatic autoregulation with a matched decrease of glycogenolysis (12). Therefore, in addition to determining EGP, in the present study we also measured the contribution of gluconeogenesis and glycogenolysis to EGP. Generally, clamp studies cannot completely reflect the complex metabolic situation observed in the postprandial state, e.g., after the intake of a high-fat meal. When using hyperinsulinemic clamps, elevation of FFA concentrations is known to impair insulin-mediated suppression of EGP (4). However, hyperinsulinemic conditions might obscure effects of FFA particularly on glycogenolysis, which is known to be sensitive even to very small increases in insulin concentrations (10, 15). In studies not using clamp conditions, another problem arises in that FFA potently increase insulin secretion (4). To circumvent these potential problems we used an infusion of somatostatin and the replacement of insulin and glucagon at low fasting doses, which allowed plasma glucose concentrations to increase freely in response to lipid infusion (6, 26) and was furthermore likely to reduce potential interference of higher insulin doses, particularly with glycogenolysis.

The experimental conditions for matched Ala/Ala94 carriers and wild types were identical in the present study. Potential differences in somatostatin responsiveness between L-FABP genotypes were unlikely, as indicated by near-complete somatostatin-induced suppression of C-peptide and growth hormone concentrations in all subjects, with no difference between L-FABP genotypes. However, the chosen experimental design might have been advantageous for a proof of principle, and we cannot exclude that the metabolic effects of systemic vs. portal lipid administration might be distinct. In addition, we investigated healthy persons with normal glucose metabolism, and potential effects of the Ala/Ala94 variant in patients with high blood lipids, diabetes, and obesity are as yet unknown. Another important limitation was the small number of participants in the intervention studies. However, phenotypical differences between lipid-exposed L-FABP genotypes in the present study were pronounced, statistically significant, and are in agreement with the phenotype observed in L-FABP knockout mice (22).

In conclusion, the common Ala/Ala94 amino acid variant in L-FABP contributed significantly to decreased hepatic glycogenolysis and less severe hyperglycemia in lipid-challenged humans. Investigation of L-FABP phenotypes in the basal, overnight-fasted state yielded only incomplete information. It can be hypothesized that L-FABP may not play a significant role in a normal diet but may contribute to disturbed glucose metabolism in a high-fat diet.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 CONCLUSIONS
 GRANTS
REFERENCES
 
This study was supported by grants from the German Ministry of Education and Science (BMBF 0313042C), from the Austrian Science Fund (FWF P15656 [GenBank] ), and from the National Institutes of Health (DK-14507).


   ACKNOWLEDGMENTS
 
We thank Andreas Wagner, Matthias Nestler, Andrea Ziegenhorn, and Katrin Sprengel for outstanding technical assistance and Annekathrin Mähler for collaboration in genotyping subjects.


   FOOTNOTES
 

Address for reprint requests and other correspondence: M. O. Weickert, Dept. of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany (e-mail: m.weickert{at}dife.de)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 CONCLUSIONS
 GRANTS
 REFERENCES
 

  1. Atshaves BP, McIntosh AM, Lyuksyutova OI, Zipfel W, Webb WW, Schroeder F. Liver fatty acid-binding protein gene ablation inhibits branched-chain fatty acid metabolism in cultured primary hepatocytes. J Biol Chem 279: 30954–30965, 2004.[Abstract/Free Full Text]
  2. Baron AD, Kolterman OG, Bell J, Mandarino LJ, Olefsky JM. Rates of noninsulin-mediated glucose uptake are elevated in type II diabetic subjects. J Clin Invest 76: 1782–1788, 1985.[Web of Science][Medline]
  3. Bass NM, Manning JA. Tissue expression of three structurally different fatty acid binding proteins from rat heart muscle, liver, and intestine. Biochem Biophys Res Commun 137: 929–935, 1986.[CrossRef][Web of Science][Medline]
  4. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46: 3–10, 1997.[Abstract]
  5. Boden G, Chen X, Capulong E, Mozzoli M. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 50: 810–816, 2001.[Abstract/Free Full Text]
  6. Boden G, Jadali F. Effects of lipid on basal carbohydrate metabolism in normal men. Diabetes 40: 686–692, 1991.[Abstract]
  7. Brouillette C, Bosse Y, Perusse L, Gaudet D, Vohl MC. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J Hum Genet 49: 424–432, 2004.[Web of Science][Medline]
  8. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42: 987–1000, 2005.[CrossRef][Web of Science]
  9. Chandramouli V, Ekberg K, Schumann WC, Kalhan SC, Wahren J, Landau BR. Quantifying gluconeogenesis during fasting. Am J Physiol Endocrinol Metab 273: E1209–E1215, 1997.[Abstract/Free Full Text]
  10. Cherrington AD, Edgerton D, Sindelar DK. The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia 41: 987–996, 1998.[CrossRef][Web of Science][Medline]
  11. Chu CA, Sherck SM, Igawa K, Sindelar DK, Neal DW, Emshwiller M, Cherrington AD. Effects of free fatty acids on hepatic glycogenolysis and gluconeogenesis in conscious dogs. Am J Physiol Endocrinol Metab 282: E402–E411, 2002.[Abstract/Free Full Text]
  12. Clore JN, Glickman PS, Nestler JE, Blackard WG. In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans. Am J Physiol Endocrinol Metab 261: E425–E429, 1991.[Abstract/Free Full Text]
  13. Couillard C, Bergeron N, Prud'homme D, Bergeron J, Tremblay A, Bouchard C, Mauriege P, Despres JP. Postprandial triglyceride response in visceral obesity in men. Diabetes 47: 953–960, 1998.[Abstract]
  14. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 237: E214–E223, 1979.[Abstract/Free Full Text]
  15. Edgerton DS, Cardin S, Emshwiller M, Neal D, Chandramouli V, Schumann WC, Landau BR, Rossetti L, Cherrington AD. Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism. Diabetes 50: 1872–1882, 2001.[Abstract/Free Full Text]
  16. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72: 1737–1747, 1983.[Web of Science][Medline]
  17. Hother-Nielsen O, Beck-Nielsen H. On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. Diabetologia 33: 603–610, 1990.[CrossRef][Web of Science][Medline]
  18. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 98: 378–385, 1996.[Web of Science][Medline]
  19. Liljenquist JE, Mueller GL, Cherrington AD, Keller U, Chiasson JL, Perry JM, Lacy WW, Rabinowitz D. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 59: 369–374, 1977.[Web of Science][Medline]
  20. Makowski L, Hotamisligil GS. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 16: 543–548, 2005.[Web of Science][Medline]
  21. Newberry EP, Xie Y, Kennedy S, Han X, Buhman KK, Luo J, Gross RW, Davidson NO. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem 278: 51664–51672, 2003.[Abstract/Free Full Text]
  22. Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 44: 1191–1205, 2006.[CrossRef][Web of Science][Medline]
  23. Radziuk J, Lickley HL. The metabolic clearance of glucose: measurement and meaning. Diabetologia 28: 315–322, 1985.[Web of Science][Medline]
  24. Robitaille J, Brouillette C, Lemieux S, Perusse L, Gaudet D, Vohl MC. Plasma concentrations of apolipoprotein B are modulated by a gene—diet interaction effect between the LFABP T94A polymorphism and dietary fat intake in French-Canadian men. Mol Genet Metab 82: 296–303, 2004.[CrossRef][Web of Science][Medline]
  25. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97: 2859–2865, 1996.[Web of Science][Medline]
  26. Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhausl W, Shulman GI. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. Diabetes 49: 701–707, 2000.[Abstract]
  27. Schumann WC, Gastaldelli A, Chandramouli V, Previs SF, Pettiti M, Ferrannini E, Landau BR. Determination of the enrichment of the hydrogen bound to carbon 5 of glucose on 2H2O administration. Anal Biochem 297: 195–197, 2001.[CrossRef][Web of Science][Medline]
  28. Sidossis LS, Mittendorfer B, Chinkes D, Walser E, Wolfe RR. Effect of hyperglycemia-hyperinsulinemia on whole body and regional fatty acid metabolism. Am J Physiol Endocrinol Metab 276: E427–E434, 1999.[Abstract/Free Full Text]
  29. Staehr P, Hother-Nielsen O, Landau BR, Chandramouli V, Holst JJ, Beck-Nielsen H. Effects of free fatty acids per se on glucose production, gluconeogenesis, and glycogenolysis. Diabetes 52: 260–267, 2003.[Abstract/Free Full Text]
  30. Weickert MO, Mohlig M, Schofl C, Arafat AM, Otto B, Viehoff H, Koebnick C, Kohl A, Spranger J, Pfeiffer AF. Cereal fiber improves whole-body insulin sensitivity in overweight and obese women. Diabetes Care 29: 775–780, 2006.[Abstract/Free Full Text]
  31. Weickert MO, Pfeiffer AF. Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 49: 1732–1741, 2006.[CrossRef][Web of Science][Medline]
  32. Williamson JR, Browning ET, Scholz R, Kreisberg RA, Fritz IB. Inhibition of fatty acid stimulation of gluconeogenesis by (+)-decanoylcarnitine in perfused rat liver. Diabetes 17: 194–208, 1968.[Web of Science][Medline]
  33. Yang D, Diraison F, Beylot M, Brunengraber DZ, Samols MA, Anderson VE, Brunengraber H. Assay of low deuterium enrichment of water by isotopic exchange with [U-13C3]acetone and gas chromatography-mass spectrometry. Anal Biochem 258: 315–321, 1998.[CrossRef][Web of Science][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/4/E1078    most recent
00337.2007v2
00337.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weickert, M. O.
Right arrow Articles by Möhlig, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weickert, M. O.
Right arrow Articles by Möhlig, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.